AG真人官方

Charles E. Collins IV, Chief Executive Officer of Argan, Inc. (AGX), reported amended insider transactions on Form 4/A. On 07/29/2025 he exercised 1,500 stock options at $46.35 and sold the same 1,500 shares on the open market at an average price of $241.50, leaving him with 22,506 shares. On 07/31/2025 he exercised 2,735 options at $46.35 and 2,265 options at $43.10, then sold 5,000 shares on the open market at an average price of $245, resulting in 21,006 shares beneficially owned following the reported transactions. The filings list option exercise dates and original grant dates and show the exercises were from options granted 01/11/2019 and 09/12/2019. The Form is signed by Mr. Collins on 08/29/2025.

Argan, Inc. (AGX) 鈥� Form 144 insider sale notice

Insider John R. Jeffrey, Jr. has filed to sell up to 2,621 common shares through Charles Schwab on or about 29 Jul 2025. The proposed sale equals roughly 0.02 % of the 13.64 m shares outstanding and carries an aggregate market value of $623,798, implying a per-share price near $238.

The shares derive from two recent equity grants: a time-based restricted stock issuance of 390 shares on 13 Jun 2025 and an option-exercise grant of 7,731 shares on 17 Jan 2025. Over the past three months the same insider sold 5,500 shares on 9 Jun 2025 for gross proceeds of $1.20 m. The filer certifies awareness of no undisclosed adverse information and affirms compliance with Rule 144. No operational, earnings or guidance data are included in this filing.

On 28 July 2025, Argan, Inc. (NYSE: AGX) filed an Item 8.01 Form 8-K announcing that its wholly owned subsidiary, Atlantic Projects Company, has signed an engineering, procurement and construction (EPC) contract with SSE Thermal for the Platin Power Station in County Meath, Ireland. The plant will employ three Siemens Energy SGT-800 turbines operating in open-cycle mode and is designed to deliver approximately 170 MW of peaking capacity to the Irish grid during demand spikes. Target completion is in 2028.

The filing states that the entire contract value will be added to Argan鈥檚 consolidated project backlog for the period ending 31 July 2025, but the dollar amount was not disclosed. No additional financial guidance, funding details or regulatory contingencies were provided. The disclosure does not amend any prior financial statements.

While the contract enhances multi-year revenue visibility, investors lack information on margin potential, payment schedule or risk-sharing terms, making it difficult to gauge precise earnings impact.

Argan, Inc. (AGX) 鈥� Form 4 Insider Transaction Summary

Director Peter W. Getsinger reported three transactions involving the company鈥檚 common stock:

• Sale: On 26 Jun 2025, he sold 3,456 shares in the open market at $212.01 per share, generating roughly $732.7 thousand in proceeds.
• Gift to Donor-Advised Fund: On 30 Jun 2025, he transferred 1,000 shares at no consideration to a donor-advised fund managed by Martha鈥檚 Vineyard Investment Advisors.
• Family Gift: On the same date, he gifted 999 shares (333 shares each) to his three children.

Following these transactions, Getsinger鈥檚 direct beneficial ownership declined from 18,351 to 12,896 shares, a 29.7 % reduction. No derivative securities were reported.

The filing does not indicate that the sale was executed under a Rule 10b5-1 trading plan. Investors often view sizeable insider sales鈥攑articularly absent a preset plan鈥攁s a potential negative sentiment signal, although philanthropic gifts may be neutral with respect to corporate outlook.